Data presented at the ASCO Gastrointestinal Cancers Symposium showed the regimen may be a new option, but it comes with more treatment and financial toxicity.
T-cells from the liver and lymph nodes show promising potential for future treatments of liver cancer, according to a new ...
About 61% of patients with stage I or II dMMR colon cancer achieved a pathologic complete response after a single cycle of neoadjuvant pembrolizumab, new data revealed.
Bristol Myers Squibb (BMS) has shared promising results from a late-stage study of its dual immunotherapy combination in ...
Median duration of therapy was 20.5 months for the combination and 16.4 months with single-agent nivolumab. Median number of ...
Metastatic colorectal cancer with microsatellite instability-high or mismatch repair-deficient status represents a distinct ...
Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback